FibroKey™
Precision Multiplex Monitoring of Fibrosis Biomarkers in Chronic Kidney Disease – Tracking Disease Progression and Therapeutic Response
Fibrosis Mechanisms
Chronic Kidney Disease (CKD) affects millions worldwide and is a leading cause of morbidity and mortality. Early detection of fibrotic processes is crucial for developing therapeutic strategies to mitigate the loss of kidney function
FibroKey™ is a multiplexed MS-based assay delivering a robust solution for monitoring fibrosis mechanisms through the quantification of over 35 validated biomarkers in urine. This assay leverages mass spectrometry to provide detailed insights into the fibrotic processes involved in CKD, supporting both clinical and therapeutic research.
FibroKey™ features a robust panel of 30+ fibrosis-related biomarkers, providing a thorough overview of the extracellular matrix (ECM) remodeling and inflammatory processes central to chronic kidney disease (CKD). 22 of these biomarkers were detected at endogenous levels in CKD patients, with 17 quantified absolutely and five measured relatively. This targeted selection provides comprehensive insights into CKD progression, supporting effective monitoring and therapeutic development. Among the dozens of markers included, key highlights include:
- ANXA1 – Linked to anti-inflammatory responses and tissue repair.
- CD44 – A cell-surface glycoprotein involved in cell communication and ECM interaction.
- MMP7 – A matrix metalloproteinase essential for ECM degradation.
- ICAM1 – Plays a critical role in inflammatory responses and immune cell adhesion.
Each marker is carefully validated through the InoKey™ workflow, ensuring precision and reproducibility. This comprehensive biomarker panel enables precise monitoring and tracking of therapeutic efficacy, supporting research into various stages of CKD and other fibrotic diseases.
Read our case study and learn more about 35+ biomarkers selected and validated for FibroKey™
FibroKey™ enables precise disease monitoring with mass spectrometry-based quantification of fibrosis biomarkers. Its multiplex design reduces the need for multiple tests, offering a more efficient approach to understanding fibrosis pathways.
Researchers can gain real-time insights into disease progression and therapeutic efficacy through FibroKey’s ability to monitor fibrosis through urine samples, providing an alternative to traditional invasive procedures.
FibroKey™ leverages the power of mass spectrometry to detect biomarkers at low concentrations, offering high sensitivity and specificity across fibrosis-related pathways. This ensures that even subtle changes in disease progression are accurately captured, providing reliable data for drug development and clinical studies.
Please Note: Certain markers may be below the limit of detection (LOD) in healthy human populations, with higher detectability observed in disease-specific states.
Accelerating Clinical Trial Timelines
Obtain definitive insights into your Fibrosis research goals
- Urine Specimens
- Blood Plasma
- FFPE Tissue Samples
- Serum
- Chronic Kidney Disease (CKD)
- Liver and Kidney Fibrosis
- Drug development and therapeutic monitoring
- Early-stage fibrosis detection and biomarker validation
- Statistical Analysis
- Graphical Data Representation
- Correlation Matrices
- Quantitative Values
End-to-End Solution
The Biomarker Strategy for Success
Measure proteins which pharmaceutical companies care about at the precision needed to enable decision-making and FDA submissions in three easy steps
Send
Samples
After designing your custom experimental assay with our with our proteomics experts, send your non-invasive urine samples to our CLIA, FDA-inspected (US), or GCP/GLP (UK) certified labs.
Quantification and Analysis
FibroKey™ utilizes mass spectrometry to quantify proteins involved in fibrosis—detailed analysis of fibrosis markers, providing insights into disease progression and treatment efficacy.
Therapeutic Evaluation
The assay supports therapeutic evaluation by offering extended validation for exploratory and secondary endpoints. This ensures reliable data for clinical trials or LDTs, enabling precise monitoring of therapeutic impact and disease progression.
